- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.06. | Pharmala Biotech Holdings Inc: Pharmala files prospectus to issue $50M of securities | 1 | Stockwatch | ||
| PHARMALA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 20.06. | PharmAla Biotech: PharmAla Files Preliminary Base Shelf Prospectus | 1 | GlobeNewswire (USA) | ||
| 04.06. | Pharmala Biotech Holdings Inc: Pharmala completes shipment of LaNeo MDMA to Yale | 2 | Stockwatch | ||
| 03.06. | PharmAla Biotech: PharmAla Completes Shipment of LaNeo MDMA to Yale University, Provides Investor Update | 1 | GlobeNewswire (USA) | ||
| 30.05. | Pharmala Biotech Holdings Inc: Pharmala sniffs out counterfeit nasal spray on-line | 2 | Stockwatch | ||
| 30.05. | PharmAla warns against fake MDMA products bearing its name | 1 | The Market Herald Canada | ||
| 30.05. | PharmAla Biotech Warns Against Fake Products Claiming to be Made by PharmAla | 154 | GlobeNewswire (Europe) | TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing... ► Artikel lesen | |
| 15.05. | PharmAla Biotech Launches Phenesafe AI Drug Discovery Platform for Novel Phenethylamines | 3 | GlobeNewswire (USA) | ||
| 30.04. | PharmAla Biotech: PharmAla Issues Q2 Financial Statements | 1.135 | GlobeNewswire (Europe) | TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| 24.03. | Pharmala Biotech Holdings Inc: Pharmala contracts third party logistics outfit in U.S. | 3 | Stockwatch | ||
| 24.03. | PharmAla Biotech: PharmAla Contracts with Partner to Act as US Distributor | 3 | GlobeNewswire (USA) | ||
| 21.03. | Pharmala Biotech Holdings Inc: Pharmala ships LaNeo MDMA to University of Washington | 3 | Stockwatch | ||
| 21.03. | PharmAla Biotech: PharmAla Completes Shipment of LaNeo MDMA to the University of Washington | 2 | GlobeNewswire (USA) | ||
| 10.03. | Pharmala Biotech Holdings Inc: Pharmala enters Dutch distribution deal with Duchefa | 1 | Stockwatch | ||
| 10.03. | PharmAla Biotech: PharmAla Signs Duchefa Farma as Exclusive Distributor in Netherlands | 267 | GlobeNewswire (Europe) | TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| 04.03. | Pharmala Biotech Holdings Inc: Pharmala completes shipment of LaNeo MDMA to UCLA | 1 | Stockwatch | ||
| 03.03. | PharmAla Biotech: PharmAla Completes Shipment of LaNeo MDMA to UCLA for Schizophrenia Study | 1 | GlobeNewswire (USA) | ||
| 28.02. | Pharmala Biotech Holdings Inc: Pharmala's UT Health contract to move forward | 3 | Stockwatch | ||
| 27.02. | PharmAla Biotech: PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo MDMA | 1 | GlobeNewswire (USA) | ||
| 07.02. | Pharmala Biotech Holdings Inc: Pharmala Biotech hires Azrieli for advisory services | 2 | Stockwatch |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 7,110 | +4,37 % | EQS-Adhoc: Evotec SE: Evotec passt Umsatzprognose an und bestätigt Gewinnprognose | EQS-Ad-hoc: Evotec SE / Schlagwort(e): Prognoseänderung
Evotec SE passt Umsatzprognose an und bestätigt Gewinnprognose
21.07.2025 / 11:25 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,255 | 0,00 % | Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? | ||
| IMMUNOVANT | 18,320 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 | Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD)... ► Artikel lesen | |
| QIAGEN | 43,580 | +1,99 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 48 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis "diagnostiziert" eine defensive... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 14,630 | 0,00 % | Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies | - New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings -- Ongoing pivotal trial and FDA Type C meeting provide... ► Artikel lesen | |
| JANUX THERAPEUTICS | 25,970 | 0,00 % | Raymond James startet Coverage für Janux Therapeutics mit "Outperform"-Rating | ||
| VERVE THERAPEUTICS | 11,130 | 0,00 % | Lilly completes tender offer for Verve Therapeutics shares | ||
| VIR BIOTECHNOLOGY | 5,760 | 0,00 % | Vir Biotechnology, Inc. - 8-K, Current Report | ||
| SANA BIOTECHNOLOGY | 5,125 | 0,00 % | Citi Maintained a Buy Rating on Sana Biotechnology (SANA) | ||
| BEAM THERAPEUTICS | 20,960 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 27,545 | 0,00 % | Summit Therapeutics vor Mega-Deal: Aktie +15% | Papiere von Summit Therapeutics legen heute in der Spitze um +15% zu. Vorausgegangen ist ein Bloomberg-Bericht um einen bevorstehenden Mega-Deals mit dem Pharmakonzern AstraZeneca. Laut Bloomberg News... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 14,950 | 0,00 % | EU Grants Marketing Authorization For KOSTAIVE To CSL And Arcturus Therapeutics | CANBERA (dpa-AFX) - Biotechnology firm CSL Ltd. (CSL.AX, CMXHF.PK) and sa-mRNA pioneer Arcturus Therapeutics Ltd. (ARCT) announced Friday that the European Commission has granted marketing authorization... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,310 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| UPSTREAM BIO | 13,350 | 0,00 % | Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD) | - Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD - - Broadens global development program for... ► Artikel lesen | |
| VALNEVA | 3,276 | -4,77 % | BioTech wird zu Gold: Wer schluckt wen oder was? Auf der Liste sind Evotec, BioNxt, Valneva und Formycon! | Der BioTech-Sektor blickt mit Argusaugen auf das Zinsniveau der Notenbanken. Aktuell allerdings scheint die Inflation noch etwas zu hoch, um massive Senkungen zu erwarten. So hat auch die EZB gestern... ► Artikel lesen |
PHARMALA BIOTECH HOLDINGS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMALA BIOTECH HOLDINGS INC finden Sie auf Wallstreet Online.